ADVI Analysis: MACPAC Meeting September 2023

Pharmaceuticals and Biotech Federal And State Policy Pharmaceuticals and Biotech

October 6, 2023

The Medicaid and CHIP Payment and Access Commission (MACPAC) held its latest meeting on September 21-22, 2023 (link). The following relevant topics were discussed: Monitoring and oversight of managed care denials and appeals, Medicaid unwinding: Challenges to date and what's to come, and Ex parte renewals. Read the ADVI Angle on key takeaways.

The Medicaid and CHIP Payment and Access Commission (MACPAC) held its latest meeting on September 21-22, 2023 (link). The following relevant topics were discussed. 

  • Monitoring and oversight of managed care denials and appeals
  • Medicaid unwinding: Challenges to date and what’s to come
  • Ex parte renewals

ADVI Angle

The following are key takeaways from the September Meeting

  • Monitoring and oversight of managed care denials and appeals
    • Commissioners were broadly supportive of 4 policy options that aim to improve data collection and monitoring, the use of clinical audits, and public reporting related to Medicaid managed care denials and appeals.
    • MACPAC staff will move forward with developing the policy options into formal recommendations (timeline not specified).
  • Medicaid unwinding: Challenges to date and what’s to come 
    • Commissioners broadly supported continued data collection on disenrollments, even after the unwinding period concludes.
    • Commissioners also discussed the need for increased communication between the states and CMS and including stakeholders in policy development discussions.
  • Ex parte renewals
    • The Commission discussed findings from an Ex Parte Roundtable held June 27 and 29, 2023. Attendees to the roundtable included CMS representatives, representatives from six Medicaid agencies, policy experts, beneficiary advocates, and IT system vendors. MACPAC staff intend to publish an issue brief with the findings from the roundtable in coming weeks (timeline not specified).

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Medicare Negotiation Program Deselection: Analysis of Previously Deselected Drugs and Likely Fall 2026 Targets

Authored by Allison Schneider, MHA, and Lindsay Bealor Greenleaf, JD, MBA Under the Inflation Reduction Act, drugs selected for the …

November 4, 2026

Health Policy & Access Strategy Inflation Reduction Act

Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy

Gain immediate access to actionable insights from CMS and ADVI Health policy leaders. From the Medicare Drug Price Negotiation Program …

October 2, 2026

Health Policy & Access Strategy Inflation Reduction Act

Analysis of 340B modifier usage in Medicare Part B claims

Analysis of Part B Claims from January 2025 through June 2026 Prepared By:Johanna Celli, Pete Kardel, Caitlin Sheetz, ADVI Health’s …

September 30, 2026

Precision Medicine

CMS Proposes RAPID Coverage Pathway for Breakthrough Devices

IVDs remain outside scope, while FDA-CMS Parallel Review remains available. KEY TAKEAWAY RAPID could materially shorten the gap between Food …

August 21, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.